Menu
Search Close

News

Interim Results for the six month period to 31 October 2008

15th January 2009

The Directors of Scancell Holdings plc, the parent company of Scancell Limited (‘Scancell’),
the developer of cancer vaccines based on its patented ImmunoBody™ platform, are pleased
to announce the interim results for Scancell for the six month period ended 31st October 2008
(‘the period’).

Highlights:

  • Admitted to Plus markets on 24 September 2008 and raised £1.559,502 on 24th September 2008
  • Issue of equity raised £43,999.8 on the 19th of December 2008
  • Following the placing of shares in September, the Company has £2,220,479 cash reserves
  • Continued make good progress towards its goal of starting Phase 1 clinical trials with SCIB1 in 2010
  • Agreement to license key components of SCIB1 from National Institute for Health (‘NIH’) in the final phase of negotiation
  • Negotiations to secure development and commercial rights to an injection device to deliver SCIB1 to patients progressing wel
  • Experienced Development Advisor appointed for SCIB1
  • Presented at the Genesis 2008 Oncology Showcase

David Evans, Non-Executive Chairman of Scancell, commented:

“I am delighted to report a very successful first six months as a public company. In 2008, we raised £1.6m in conjunction with being admitted to Plus markets. The funds raised will provide the ability to further develop Scancell’s core technology; the ImmunoBodyTM platform and to achieve its aim of starting Phase 1 clinical trials of SCIB1 in 2010.”

For further information contact:

Company:
Scancell Holdings Plc  -  Professor Lindy Durrant/  -  Tel: 020 7245 1100
                                       Dr Richard Goodfellow

Corporate Advisers:
St Helen's Capital Plc  -  Duncan Vasey/  -  Tel: 020 7628 5582
                                       Barry Hocken

Financial PR:
Hansard Group  -  Adam Reynolds/  -  Tel: 020 7245 1100
                             Vicky Krause

View the full results 

Webcasts, Interviews and Media Coverage

Scancell to begin dosing in UK phase II trial of flagship skin cancer drug

Cliff Holloway, CEO of Scancell Holdings PLC (LON:SCLP), speaks to Proactive London's Andrew Scott after announcing they're to kick off the UK arm of the phase II clinical trial of its flagship skin cancer drug.

The study will test the safety and efficacy of SCIB1 in 25 metastatic melanoma patients who are also receiving Merck’s checkpoint inhibitor Pembrolizumab.

Thu, 25 Apr 2019 10:56:00

Scancell higher as it is to begin UK arm of phase II skin cancer trial within weeks

The mid-stage study is testing Scancell’s flagship skin cancer immunotherapy in combination with Keytruda – the blockbuster checkpoint inhibitor developed by Merck

Thu, 25 Apr 2019 12:20:00

Scancell Holdings wins Japanese patent protection

It follows on from similar awards in key markets such as the US, Europe, South Africa and Australia

Mon, 08 Apr 2019 08:20:00